PureTech Health (LON:PRTC) Trading Down 15.2% – Should You Sell?

PureTech Health plc (LON:PRTCGet Free Report) shares fell 15.2% on Wednesday . The company traded as low as GBX 117.20 ($1.50) and last traded at GBX 117.20 ($1.50). 42,764,352 shares were traded during mid-day trading, an increase of 2,645% from the average session volume of 1,557,904 shares. The stock had previously closed at GBX 138.20 ($1.77).

Analyst Upgrades and Downgrades

Separately, Jefferies Financial Group restated a “buy” rating and issued a GBX 455 ($5.81) price target on shares of PureTech Health in a research report on Monday, December 16th.

Read Our Latest Analysis on PureTech Health

PureTech Health Trading Down 4.9 %

The company has a market capitalization of £335.83 million, a PE ratio of -4.59 and a beta of 1.02. The company has a fifty day simple moving average of GBX 138.62 and a 200-day simple moving average of GBX 149.16. The company has a current ratio of 3.68, a quick ratio of 2.51 and a debt-to-equity ratio of 45.82.

About PureTech Health

(Get Free Report)

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.

See Also

Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.